{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:09:47Z","timestamp":1793984987435,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10637-022-01256-0","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T12:02:40Z","timestamp":1653134560000},"page":"861-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rare ocular toxicity induced by pertuzumab\/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Junlong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"1256_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1158\/0008-5472.can-03-3856","volume":"64","author":"R Nahta","year":"2004","unstructured":"Nahta R, Hung M-C, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343\u20132346. https:\/\/doi.org\/10.1158\/0008-5472.can-03-3856","journal-title":"Cancer Res"},{"key":"1256_CR2","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1158\/1078-0432.CCR-13-1212","volume":"19","author":"GM Blumenthal","year":"2013","unstructured":"Blumenthal GM, Scher NS, Cortazar P et al (2013) First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 19:4911\u20134916. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1212","journal-title":"Clin Cancer Res"},{"key":"1256_CR3","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-18-3003","volume":"25","author":"LJ Howie","year":"2019","unstructured":"Howie LJ, Scher NS, Amiri-Kordestani L et al (2019) FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. Clin Cancer Res 25:2949\u20132955. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3003","journal-title":"Clin Cancer Res"},{"key":"1256_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im Y-H et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17:791\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(16)00163-7","journal-title":"Lancet Oncol"},{"key":"1256_CR5","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-14-1268","volume":"20","author":"L Amiri-Kordestani","year":"2014","unstructured":"Amiri-Kordestani L, Wedam S, Zhang L et al (2014) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 20:5359\u20135364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1268","journal-title":"Clin Cancer Res"},{"key":"1256_CR6","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"1256_CR7","doi-asserted-by":"publisher","first-page":"15530","DOI":"10.1038\/s41598-020-72661-9","volume":"10","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Hattori N, Fujii S et al (2020) Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Sci Rep 10:15530. https:\/\/doi.org\/10.1038\/s41598-020-72661-9","journal-title":"Sci Rep"},{"key":"1256_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2016.1167185","volume":"15","author":"J Gao","year":"2016","unstructured":"Gao J, Swain SM (2016) Pertuzumab for the treatment of breast cancer: a safety review. Expert Opin Drug Saf 15:853\u2013863. https:\/\/doi.org\/10.1517\/14740338.2016.1167185","journal-title":"Expert Opin Drug Saf"},{"key":"1256_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2217\/fon-2018-0896","volume":"15","author":"D Eiger","year":"2019","unstructured":"Eiger D, Pond\u00e9 NF, de Azambuja E (2019) Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncol 15:1823\u20131843. https:\/\/doi.org\/10.2217\/fon-2018-0896","journal-title":"Future Oncol"},{"key":"1256_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"1256_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138\u20131144. https:\/\/doi.org\/10.1200\/JCO.2009.24.2024","journal-title":"J Clin Oncol"},{"key":"1256_CR12","unstructured":"FDA database: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125409Orig1s000ChemR.pdf"},{"key":"1256_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency database: www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/450045_4291424A1020_1_07"},{"key":"1256_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/dvdy.24666","volume":"247","author":"R Grifone","year":"2018","unstructured":"Grifone R, Saquet A, Xu Z et al (2018) Expression patterns of Rbm24 in lens, nasal epithelium, and inner ear during mouse embryonic development. Dev Dyn 247:1160\u20131169. https:\/\/doi.org\/10.1002\/dvdy.24666","journal-title":"Dev Dyn"},{"key":"1256_CR15","doi-asserted-by":"publisher","first-page":"7245","DOI":"10.1073\/pnas.1917922117","volume":"117","author":"M Shao","year":"2020","unstructured":"Shao M, Lu T, Zhang C et al (2020) Rbm24 controls poly(A) tail length and translation efficiency of crystallin mRNAs in the lens via cytoplasmic polyadenylation. Proc Natl Acad Sci USA 117:7245\u20137254. https:\/\/doi.org\/10.1073\/pnas.1917922117","journal-title":"Proc Natl Acad Sci USA"},{"key":"1256_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1523\/JNEUROSCI.3664-04.2005","volume":"25","author":"X Yi","year":"2005","unstructured":"Yi X, Schubert M, Peachey NS et al (2005) Insulin receptor substrate 2 is essential for maturation and survival of photoreceptor cells. J Neurosci 25:1240\u20131248. https:\/\/doi.org\/10.1523\/JNEUROSCI.3664-04.2005","journal-title":"J Neurosci"},{"key":"1256_CR17","doi-asserted-by":"publisher","first-page":"151726","DOI":"10.1016\/j.aanat.2021.151726","volume":"239","author":"MC Iglesias-Osma","year":"2022","unstructured":"Iglesias-Osma MC, Blanco EJ, Carretero-Hern\u00e1ndez M et al (2022) The lack of Irs2 induces changes in the immunocytochemical expression of aromatase in the mouse retina. Ann Anat 239:151726. https:\/\/doi.org\/10.1016\/j.aanat.2021.151726","journal-title":"Ann Anat"},{"key":"1256_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.exer.2003.07.007","volume":"77","author":"RT Libby","year":"2003","unstructured":"Libby RT, Kitamoto J, Holme RH et al (2003) Cdh23 mutations in the mouse are associated with retinal dysfunction but not retinal degeneration. Exp Eye Res 77:731\u2013739. https:\/\/doi.org\/10.1016\/j.exer.2003.07.007","journal-title":"Exp Eye Res"},{"key":"1256_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jmedgenet-2011-100262","volume":"48","author":"JM Schultz","year":"2011","unstructured":"Schultz JM, Bhatti R, Madeo AC et al (2011) Allelic hierarchy of CDH23 mutations causing non-syndromic deafness DFNB12 or Usher syndrome USH1D in compound heterozygotes. J Med Genet 48:767\u2013775. https:\/\/doi.org\/10.1136\/jmedgenet-2011-100262","journal-title":"J Med Genet"},{"key":"1256_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","volume":"81","author":"EM Brown","year":"2001","unstructured":"Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239\u2013297. https:\/\/doi.org\/10.1152\/physrev.2001.81.1.239","journal-title":"Physiol Rev"},{"key":"1256_CR21","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1073\/pnas.0405516101","volume":"101","author":"TA Hough","year":"2004","unstructured":"Hough TA, Bogani D, Cheeseman MT et al (2004) Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc Natl Acad Sci USA 101:13566\u201313571. https:\/\/doi.org\/10.1073\/pnas.0405516101","journal-title":"Proc Natl Acad Sci USA"},{"key":"1256_CR22","doi-asserted-by":"publisher","first-page":"64431","DOI":"10.18632\/oncotarget.7043","volume":"7","author":"D de Melo Gagliato","year":"2016","unstructured":"de Melo Gagliato D, Jardim DLF, Marchesi MSP et al (2016) Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 7:64431\u201364446. https:\/\/doi.org\/10.18632\/oncotarget.7043","journal-title":"Oncotarget"},{"key":"1256_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ijc.24750","volume":"126","author":"SE Ghayad","year":"2010","unstructured":"Ghayad SE, Vendrell JA, Ben Larbi S et al (2010) Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K\/Akt signaling pathways. Int J Cancer 126:545\u201362. https:\/\/doi.org\/10.1002\/ijc.24750","journal-title":"Int J Cancer"},{"key":"1256_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127\u201337. https:\/\/doi.org\/10.1038\/35052073","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1256_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","volume":"27","author":"N Stjepanovic","year":"2016","unstructured":"Stjepanovic N, Velazquez-Martin JP, Bedard PL (2016) Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 27:998\u20131005. https:\/\/doi.org\/10.1093\/annonc\/mdw100","journal-title":"Ann Oncol"},{"key":"1256_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.tips.2019.09.009","volume":"40","author":"TV Tkatchenko","year":"2019","unstructured":"Tkatchenko TV, Tkatchenko AV (2019) Pharmacogenomic approach to antimyopia drug development: Pathways lead the way. Trends Pharmacol Sci 40:833\u2013852. https:\/\/doi.org\/10.1016\/j.tips.2019.09.009","journal-title":"Trends Pharmacol Sci"},{"key":"1256_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","volume":"20","author":"Z Liu","year":"2001","unstructured":"Liu Z, Carvajal M, Carraway CA et al (2001) Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia. Cornea 20:81\u201385. https:\/\/doi.org\/10.1097\/00003226-200101000-00016","journal-title":"Cornea"},{"key":"1256_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.survophthal.2014.02.004","volume":"59","author":"WJ Kheir","year":"2014","unstructured":"Kheir WJ, Sniegowski MC, El-Sawy T et al (2014) Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv Ophthalmol 59:493\u2013502. https:\/\/doi.org\/10.1016\/j.survophthal.2014.02.004","journal-title":"Surv Ophthalmol"},{"key":"1256_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1186\/s12885-015-1969-3","volume":"15","author":"A Orlandi","year":"2015","unstructured":"Orlandi A, Fasciani R, Cassano A et al (2015) Trastuzumab-induced corneal ulceration: successful no-drug treatment of a \u201cblind\u201d side effect in a case report. BMC Cancer 15:973. https:\/\/doi.org\/10.1186\/s12885-015-1969-3","journal-title":"BMC Cancer"},{"key":"1256_CR30","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1167\/iovs.04-0119","volume":"45","author":"K-P Xu","year":"2004","unstructured":"Xu K-P, Riggs A, Ding Y et al (2004) Role of ErbB2 in corneal epithelial wound healing. Invest Ophthalmol Vis Sci 45:4277\u20134283. https:\/\/doi.org\/10.1167\/iovs.04-0119","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1256_CR31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","volume":"175","author":"E Deklerck","year":"2019","unstructured":"Deklerck E, Denys H, Kreps EO (2019) Corneal features in trastuzumab emtansine treatment: not a rare occurrence. Breast Cancer Res Treat 175:525\u2013530. https:\/\/doi.org\/10.1007\/s10549-019-05179-y","journal-title":"Breast Cancer Res Treat"},{"key":"1256_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","volume":"91","author":"WL Ho","year":"2013","unstructured":"Ho WL, Wong H, Yau T (2013) The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 91:604\u2013609. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02518.x","journal-title":"Acta Ophthalmol"},{"key":"1256_CR33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","volume":"50","author":"O Huillard","year":"2014","unstructured":"Huillard O, Bakalian S, Levy C et al (2014) Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer 50:638\u2013648. https:\/\/doi.org\/10.1016\/j.ejca.2013.10.016","journal-title":"Eur J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01256-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:50Z","timestamp":1678510070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01256-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the study was obtained from the Ethical Committee of Third Xiangya Hospital, Central South University. Informed consent was provided according to the Declaration of Helsinki. The patients provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflicts of interest for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}